ASNS Arsanis Inc.

2.65
-0.09  -3%
Previous Close 2.74
Open 2.77
Price To Book 1.36
Market Cap 37935837
Shares 14,315,410
Volume 11,604
Short Ratio
Av. Daily Volume 599,905

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be discontinued due to futility - June 28, 2018.
ASN100
Staphylococcus aureus

Latest News

  1. Consolidated Research: 2019 Summary Expectations for The Trade Desk, Aduro Biotech, Walker & Dunlop, California Resources, Century Casinos, and Arsanis — Fundamental Analysis, Key Performance Indications
  2. INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition
  3. Report: Exploring Fundamental Drivers Behind GTT Communications, Midstates Petroleum, Arsanis, BioTelemetry, Dolby Laboratories, and Northern Dynasty Minerals — New Horizons, Emerging Trends, and Upcoming Developments
  4. New Strong Sell Stocks for December 11th
  5. Arsanis Shares Soar on Recent Merger Agreement, Analysts Review and Target Price
  6. Biotech's Tackling Major Issues You Should Know
  7. Arsanis, X4 Pharmaceuticals Announce Merger Deal With Rare Disease Focus
  8. Today’s Research Reports on Stocks to Watch: Arsanis and Aethlon Medical
  9. Arsanis may face more layoffs after merger with X4 Pharma
  10. SHAREHOLDER ALERT: WeissLaw LLP Investigates Arsanis, Inc.
  11. The Reason Healthcare Stocks Are Being Called Home By Investors
  12. Arsanis and X4 Pharmaceuticals Agree to Merger
  13. The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut
  14. Arsanis Enters Oversold Territory
  15. INVESTOR ALERT: Investigation of Arsanis Announced by Holzer & Holzer